Face Your Fears: Virtual reality-based cognitive behavioral therapy (VR-CBT) versus standard CBT for paranoid ideations in patients with schizophrenia spectrum disorders: a randomized clinical trial

U N Jeppesen, A S Due, L Mariegaard, A Pinkham, M Vos, W Veling, M Nordentoft, L B Glenthøj, U N Jeppesen, A S Due, L Mariegaard, A Pinkham, M Vos, W Veling, M Nordentoft, L B Glenthøj

Abstract

Background: Schizophrenia spectrum disorders cause suffering for patients, relatives, and the surrounding society. Paranoid ideations, encompassing ideas of social reference and manifest persecutory delusions, are among the most frequent symptoms in this population and a cause of significant distress. Recent meta-analyses of cognitive behavioral therapy (CBT) for psychosis show small to moderate effect sizes in reducing paranoid ideations. Virtual reality-based CBT (VR-CBT) could improve therapy efficacy as exposure and behavioral experiments in VR can be optimized, individualized, and carried out in a safe environment. Few VR-CBT studies exist for paranoid ideations and there is a need for large-scale, methodologically rigorous trials.

Methods: This study is a randomized, assessor-blinded parallel-groups multi-center superiority clinical trial, fulfilling the CONSORT criteria for non-pharmacological treatment. A total of 256 patients diagnosed with schizophrenia spectrum disorder, including schizotypal disorder (ICD-10 F20-29), will be allocated to either 10 sessions of symptom-specific CBT-VR plus treatment as usual-versus 10 sessions of standard symptom-specific CBT for paranoid ideations (CBT) plus treatment as usual. All participants will be assessed at baseline, treatment end (3 months post baseline), and then 9 months post baseline. A stratified block-randomization with concealed randomization sequence will be conducted. Independent assessors blinded to the treatment will evaluate the outcome. Analysis of outcome will be carried out with the intention to treat principles. The primary outcome is ideas of social reference measured with Green Paranoid Thought Scale Part A (GPTS-A) at the cessation of treatment at 3 months post baseline. Secondary outcomes are ideas of persecution (GPTS-B), Social Interaction Anxiety Scale (SIAS), Personal and Social Performance scale (PSP), Safety Behavior Questionnaire (SBQ), and CANTAB Emotion Recognition Task.

Discussion: The trial will elucidate whether VR-CBT can enhance therapy efficacy for paranoid ideations. Additionally, Trial findings will provide evidence on the effectiveness and cost-effectiveness of VR-CBT for paranoid ideations that can guide the possible dissemination and implementation into clinical practice.

Trial registration: ClinicalTrials.gov NCT04902066 . Initial release April 9th, 2021.

Keywords: Activities of daily living; Cognitive behavioral therapy; Delusions; Ideas of reference; Paranoid ideations; Schizophrenia spectrum disorders; Schizotypal disorders; Social functioning; Virtual reality; Virtual reality exposure therapy.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flow of participants

References

    1. Rössler W, Salize HJ, Van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399–409. doi: 10.1016/j.euroneuro.2005.04.009.
    1. GBD 2019 Mental Disorders Collaborators Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137–150. doi: 10.1016/S2215-0366(21)00395-3.
    1. Green CEL, Freeman D, Kuipers E, Bebbington P, Fowler D, Dunn G, et al. Measuring ideas of persecution and social reference: The Green et al. Paranoid Thought Scales (GPTS) Psychol Med. 2008;38(1):101–111. doi: 10.1017/S0033291707001638.
    1. Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures: a preliminary report on the initial evaluation phase of the WHO Collaborative Study on Determinants of Outcome of Severe Mental Disorders. Psychol Med. 1986;16(4):909–928. doi: 10.1017/S0033291700011910.
    1. Freeman D. Suspicious minds: the psychology of persecutory delusions. Clin Psychol Rev. 2007;27(4):425–457. doi: 10.1016/j.cpr.2006.10.004.
    1. Freeman D, Garety PA, Bebbington PE, Smith B, Rollinson R, Fowler D, et al. Psychological investigation of the structure of paranoia in a non-clinical population. Br J Psychiatry. 2005;186:427–435. doi: 10.1192/bjp.186.5.427.
    1. Startup M, Startup S. On two kinds of delusion of reference. Psychiatry Res. 2005;137(1–2):87–92. doi: 10.1016/j.psychres.2005.07.007.
    1. Wils RS, Gotfredsen DR, Hjorthøj C, Austin SF, Albert N, Secher RG, et al. Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis. Schizophr Res. 2017;182:42–48. doi: 10.1016/j.schres.2016.10.030.
    1. Austin SF, Mors O, Budtz-Jørgensen E, Secher RG, Hjorthøj CR, Bertelsen M, et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort. Schizophr Res. 2015;168(1–2):84–91. doi: 10.1016/j.schres.2015.07.021.
    1. Gotfredsen DR, Wils RS, Hjorthøj C, Austin SF, Albert N, Secher RG, et al. Stability and development of psychotic symptoms and the use of antipsychotic medication - long-term follow-up. Psychol Med. 2017;47(12):2118–2129. doi: 10.1017/S0033291717000563.
    1. Moutoussis M, Williams J, Dayan P, Bentall RP. Persecutory delusions and the conditioned avoidance paradigm: towards an integration of the psychology and biology of paranoia. Cogn Neuropsychiatry. 2007;12(6):495–510. doi: 10.1080/13546800701566686.
    1. Macdonald EM, Hayes RL, Baglioni AJ., Jr The quantity and quality of the social networks of young people with early psychosis compared with closely matched controls. Schizophr Res. 2000;46(1):25–30. doi: 10.1016/S0920-9964(00)00024-4.
    1. Loneliness and the psychosis continuum: a meta-analysis on positive psychot...: EBSCOhost. Available from: . [cited 24 Mar 2022].
    1. Stain HJ, Galletly CA, Clark S, Wilson J, Killen EA, Anthes L, et al. Understanding the social costs of psychosis: the experience of adults affected by psychosis identified within the second Australian National Survey of Psychosis. Aust N Z J Psychiatry. 2012;46(9):879–889. doi: 10.1177/0004867412449060.
    1. Turner DT, Van Der Gaag M, Karyotaki E, Cuijpers P. Psychological interventions for psychosis: A meta-analysis of comparative outcome studies. Am J Psychiatry. 2014;171(5):523–538. doi: 10.1176/appi.ajp.2013.13081159.
    1. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014;204(1):20–29. doi: 10.1192/bjp.bp.112.116285.
    1. Bighelli I, Salanti G, Huhn M, Schneider-Thoma J, Krause M, Reitmeir C, et al. Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. World Psychiatry. 2018;17(3):316–329. doi: 10.1002/wps.20577.
    1. Turner DT, Burger S, Smit F, Valmaggia LR, van der Gaag M. What Constitutes Sufficient Evidence for Case Formulation-Driven CBT for Psychosis? Cumulative Meta-analysis of the Effect on Hallucinations and Delusions. Schizophr Bull. 2020;46(5):1072–1085. doi: 10.1093/schbul/sbaa045.
    1. Lincoln TM, Peters E. A systematic review and discussion of symptom specific cognitive behavioural approaches to delusions and hallucinations. Schizophr Res. 2019;203:66–79. doi: 10.1016/j.schres.2017.12.014.
    1. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: Effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34(3):523–537. doi: 10.1093/schbul/sbm114.
    1. Freeman D, Bradley J, Antley A, Bourke E, DeWeever N, Evans N, et al. Virtual reality in the treatment of persecutory delusions: randomised controlled experimental study testing how to reduce delusional conviction. Br J Psychiatry. 2016;209(1):62–67. doi: 10.1192/bjp.bp.115.176438.
    1. Pot-Kolder RMCA, Geraets CNW, Veling W, van Beilen M, Staring ABP, Gijsman HJ, et al. Virtual-reality-based cognitive behavioural therapy versus waiting list control for paranoid ideation and social avoidance in patients with psychotic disorders: a single-blind randomised controlled trial. Lancet Psychiatry. 2018;5(3):217–226. doi: 10.1016/S2215-0366(18)30053-1.
    1. Pot-Kolder R, Veling W, Geraets C, Lokkerbol J, Smit F, Jongeneel A, et al. Cost-effectiveness of virtual reality cognitive behavioral therapy for psychosis: Health-economic evaluation within a randomized controlled trial. J Med Internet Res. 2020;22(5):1–13. doi: 10.2196/17098.
    1. Morrison AP, Turkington D, Pyle M, Spencer H, Brabban A, Dunn G, et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet. 2014;383(9926):1395–1403. doi: 10.1016/S0140-6736(13)62246-1.
    1. Jakobsen KD, Skyum E, Hashemi N, Schjerning O, Fink-Jensen A, Nielsen J. Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review. J Psychopharmacol. 2017;31(4):397–405. doi: 10.1177/0269881117695879.
    1. Rosell DR, Futterman SE, McMaster A, Siever LJ. Schizotypal personality disorder: a current review. Curr Psychiatry Rep. 2014;16(7):1–2. doi: 10.1007/s11920-014-0452-1.
    1. Mental health services in the Capital Region of Denmark - information in English. Available from: [cited 30 May 2022].
    1. English. Available from: [cited 30 May 2022].
    1. Berkhof M, van der Stouwe ECD, Lestestuiver B, van’t Hag E, van Grunsven R, de Jager J, et al. Virtual reality cognitive-behavioural therapy versus cognitive-behavioural therapy for paranoid delusions: a study protocol for a single-blind multi-Centre randomised controlled superiority trial. BMC Psychiatry. 2021;21(1) Available from: [cited 12 Apr 2022].
    1. Soll D, Fuchs R, Mehl S. Teaching Cognitive Behavior Therapy to Postgraduate Health Care Professionals in Times of COVID 19 - An Asynchronous Blended Learning Environment Proved to Be Non-inferior to In-Person Training. Front Psychol. 2021;12 Available from: [cited 18 Mar 2022].
    1. Vallis TM, Shaw BF, Dobson KS. The Cognitive Therapy Scale. Psychometric Properties. J Consult Clin Psychol. 1986;54(3):381–385.
    1. Valmaggia LR, Freeman D, Green C, Garety P, Swapp D, Antley A, et al. Virtual reality and paranoid ideations in people with an “at-risk mental state” for psychosis. Br J Psychiatry Suppl. 2007;51(SUPPL. 51):s63–s68. doi: 10.1192/bjp.191.51.s63.
    1. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther. 1998;36(4):455–470. doi: 10.1016/S0005-7967(97)10031-6.
    1. Kingsep P, Nathan P, Castle D. Cognitive behavioural group treatment for social anxiety in schizophrenia. Schizophr Res. 2003;63(1–2):121–129. doi: 10.1016/S0920-9964(02)00376-6.
    1. Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161(2):213–224. doi: 10.1016/j.psychres.2007.11.012.
    1. Freeman D, Garety PA, Kuipers E. Persecutory delusions: developing the understanding of belief maintenance and emotional distress. Psychol Med. 2001;31(7):1293–1306. doi: 10.1017/S003329170100455X.
    1. Computerized assessment in neuropsychiatry using CANTAB: discussion paper - PubMed. Available from: [cited 23 Jul 2021].
    1. EQ-5D-5L – EQ-5D. Available from: [cited 23 Jul 2021].
    1. Newnham EA, Hooke GR, Page AC. Monitoring treatment response and outcomes using the World Health Organization’s Wellbeing Index in psychiatric care. J Affect Disord. 2010;122(1–2):133–138. doi: 10.1016/j.jad.2009.06.005.
    1. Andreasen NC, Flaum M, Swayze VW, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry. 1990;47(7):615–621. doi: 10.1001/archpsyc.1990.01810190015002.
    1. Mucci A, Galderisi S, Merlotti E, Rossi A, Rocca P, Bucci P, et al. The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia. Eur Psychiatry. 2015;30(5):641–647. doi: 10.1016/j.eurpsy.2015.01.014.
    1. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;163(22):39–44. doi: 10.1192/S0007125000292581.
    1. Van Spijker BA, Batterham PJ, Calear AL, Farrer L, Christensen H, Reynolds J, et al. The suicidal ideation attributes scale (SIDAS): Community-based validation study of a new scale for the measurement of suicidal ideation. Suicide Life Threat Behav. 2014;44(4):408–419. doi: 10.1111/sltb.12084.
    1. Schultze-Lutter F, Ruhrmann S, Fusar-Poli P, Bechdolf A, G. Schimmelmann B, Klosterkotter J. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des. 2012;18(4):351–357. doi: 10.2174/138161212799316064.
    1. van der Gaag M, Schütz C, Ten Napel A, Landa Y, Delespaul P, Bak M, et al. Development of the Davos assessment of cognitive biases scale (DACOBS) Schizophr Res. 2013;144(1–3):63–71. doi: 10.1016/j.schres.2012.12.010.
    1. Luszczynska A, Scholz U, Schwarzer R. The general self-efficacy scale: multicultural validation studies. J Psychol. 2005;139(5):439–457. doi: 10.3200/JRLP.139.5.439-457.
    1. Rosset E. It’s no accident: Our bias for intentional explanations. Cognition. 2008;108(3):771–780. doi: 10.1016/j.cognition.2008.07.001.
    1. Adolphs R, Tranel D, Damasio AR. The human amygdala in social judgment. Nature. 1998;393(6684):470–474. doi: 10.1038/30982.
    1. Patterson TL, Moscona S, McKibbin CL, Davidson K, Jeste DV. Social skills performance assessment among older patients with schizophrenia. Schizophr Res. 2001;48(2–3):351–360. doi: 10.1016/S0920-9964(00)00109-2.
    1. Goldberg LR. The Development of Markers for the Big-Five Factor Structure. Psychol Assess. 1992;4(1):26–42. doi: 10.1037/1040-3590.4.1.26.
    1. Carr S, Hardy A, Fornells-Ambrojo M. The Trauma and Life Events (TALE) checklist: development of a tool for improving routine screening in people with psychosis. Eur J Psychotraumatol. 2018;9(1) Available from: [cited 23 Jul 2021].
    1. Freeman D, Loe BS, Kingdon D, Startup H, Molodynski A, Rosebrock L, et al. The revised Green et al., Paranoid Thoughts Scale (R-GPTS): Psychometric properties, severity ranges, and clinical cut-offs. Psychol Med. 2021;51(2):244–253. doi: 10.1017/S0033291719003155.
    1. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197–207. doi: 10.1016/0149-7189(79)90094-6.
    1. Center for IT og Medicoteknologi. Available from: . [cited 25 Apr 2022].
    1. Rus-Calafell M, Garety P, Sason E, Craig TJK, Valmaggia LR. Virtual reality in the assessment and treatment of psychosis: a systematic review of its utility, acceptability and effectiveness. Psychol Med. 2018;48(3):362–391. doi: 10.1017/S0033291717001945.
    1. Pinkham AE. Social cognition in schizophrenia. J Clin Psychiatry. 2014;75(SUPPL. 2):14–19. doi: 10.4088/JCP.13065su1.04.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere